Stockscreener 앱 받기
1.75
3.85%
-0.07
전일 마감가:
$1.82
열려 있는:
$1.85
하루 거래량:
2.31M
Relative Volume:
1.89
시가총액:
$100.28M
수익:
$70.00M
순이익/손실:
$-43.21M
주가수익비율:
-2.309
EPS:
-0.7579
순현금흐름:
$-34.03M
1주 성능:
-11.17%
1개월 성능:
-38.16%
6개월 성능:
-37.28%
1년 성능:
-27.98%
1일 변동 폭
$1.745
$1.9233
1주일 범위
$1.745
$2.0092
52주 변동 폭
$1.745
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
명칭
Black Diamond Therapeutics Inc
전화
617-417-5868
주소
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
1.75 | 100.28M | 70.00M | -43.21M | -34.03M | -0.7579 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-11-18 | 재개 | Piper Sandler | Overweight |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2024-07-31 | 개시 | Raymond James | Outperform |
| 2023-07-14 | 개시 | Piper Sandler | Overweight |
| 2023-06-30 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-03-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-03-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-01-07 | 개시 | Wedbush | Outperform |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | Canaccord Genuity | Buy |
| 2020-02-24 | 개시 | Cowen | Outperform |
| 2020-02-24 | 개시 | JP Morgan | Overweight |
| 2020-02-24 | 개시 | Jefferies | Buy |
모두보기
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path - sharewise.com
BDTX Stock Price, Quote & Chart - ChartMill
Black Diamond Therapeutics lung cancer drug shows 15.2-month PFS in phase 2 study - MSN
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Black Diamond Therapeutics (BDTX) Retreats 3.5% as Stock Tests Key Support ZoneMutual Fund Flow - newsline.com
What's going on with Black Diamond Therapeutics stock Tuesday? - MSN
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst - Yahoo Finance
Black Diamond Stock Outlook After Q1 Beat and Cash Runway - Eastern Progress
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know - Yahoo Finance
BDTX stock slumps on mixed phase II frontline NSCLC study data - MSN
What's Going On With Black Diamond Therapeutics Stock Tuesday? - Benzinga
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data - sharewise.com
BDTX Q1 2026 Earnings: EPS Beat but Stock Retreats 36% on Biotech VolatilityEnergy Earnings Report - newsline.com
Black Diamond Therapeutics (BDTX) Shares Tumble Nearly 35% on Clinical SetbackExpert Trade Signals - Newser
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Stifel reiterates Black Diamond Therapeutics stock rating at Buy - Investing.com
Stifel reiterates Black Diamond Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - The Manila Times
Black Diamond Therapeutics Reports Positive Phase 2 Results for Silevertinib in Frontline NSCLC With EGFR Non-Classical Mutations, Highlighting Strong CNS Activity and mPFS of 15.2 Months 13 - Minichart
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data - TipRanks
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study - Yahoo Finance
Black Diamond reports silevertinib trial results in lung cancer By Investing.com - Investing.com Australia
Black Diamond reports silevertinib trial results in lung cancer - Investing.com
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - The Manila Times
Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - Quiver Quantitative
Positive NSCLC trial results boost Black Diamond (NASDAQ: BDTX) drug hopes - Stock Titan
Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire
Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response - Stock Titan
BDTX shares gain 11% in a week: Here's what you should know - MSN
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX - RTTNews
Black Diamond to present phase 2 silevertinib trial data Thursday By Investing.com - Investing.com South Africa
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results From Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - 富途牛牛
Black Diamond to present phase 2 silevertinib trial data Thursday - Investing.com
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - The Manila Times
Black Diamond Therapeutics to Host Webcast for Investors - GlobeNewswire
BDTX Technical Analysis | Trend, Signals & Chart Patterns | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TradingKey - TradingKey
Black Diamond Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BDTX Shares Gain 11% in a Week: Here's What You Should Know - TradingView
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Black Diamond Therapeutics (NASDAQ:BDTX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond Therapeutics Inc (BDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.76%
자본화:
|
볼륨(24시간):